Predicting acute cardiac rejection from donor heart and pre-transplant recipient blood gene expression

Subscribe to email list

Please select the email list(s) to which you wish to subscribe.

You are here

Predicting acute cardiac rejection from donor heart and pre-transplant recipient blood gene expression

TitlePredicting acute cardiac rejection from donor heart and pre-transplant recipient blood gene expression
Publication TypeJournal Article
Year of Publication2013
AuthorsHollander, Z, Chen, V, Sidhu, K, Lin, D, Ng, RT, Balshaw, R, Cohen-Freue, GV, Ignaszewski, A, Imai, C, Kaan, A, Tebbutt, SJ, Wilson-McManus, JE, McMaster, RW, Keown, PA, McManus, BM, Excellence, NCECECRPROOF
JournalJOURNAL OF HEART AND LUNG TRANSPLANTATION
Volume32
Pagination259-265
Date PublishedFEB
Type of ArticleArticle
ISSN1053-2498
Keywordsacute rejection, biomarker, cardiac transplant, prediction
AbstractBACKGROUND: Acute rejection in cardiac transplant patients remains a contributory factor to limited survival of implanted hearts. Currently, there are no biomarkers in clinical use that can predict, at the time of transplantation, the likelihood of post-transplant acute cellular rejection. Such a development would be of great value in personalizing immunosuppressive treatment. METHODS: Recipient age, donor age, cold ischemic time, warm ischemic time, panel-reactive antibody, gender mismatch, blood type mismatch and human leukocyte antigens (HLA-A, -B and -DR) mismatch between recipients and donors were tested in 53 heart transplant patients for their power to predict post-transplant acute cellular rejection. Donor transplant biopsy and recipient pre-transplant blood were also examined for the presence of genomic biomarkers in 7 rejection and 11 non-rejection patients, using non-targeted data mining techniques. RESULTS: The biomarker based on the 8 clinical variables had an area under the receiver operating characteristic curve (AUC) of 0.53. The pre-transplant recipient blood gene-based panel did not yield better performance, but the donor heart tissue gene-based panel had an AUC = 0.78. A combination of 25 probe sets from the transplant donor biopsy and 18 probe sets from the pre-transplant recipient whole blood had an AUC = 0.90. Biologic pathways implicated include VEGF- and EGFR-signaling, and MAPK. CONCLUSIONS: Based on this study, the best predictive biomarker panel contains genes from recipient whole blood and donor myocardial tissue. This panel provides clinically relevant prediction power and, if validated, may personalize immunosuppressive treatment and rejection monitoring. I Heart Lung Transplant 2013;32:259-265 (C) 2013 International Society for Heart and Lung Transplantation. All rights reserved.
DOI10.1016/j.healun.2012.11.008